Press release
Phase I Funding
Regulonix has received a 12-month Phase I STTR grant from the National Institutes of Health for “Regulators of NaV1.7 Channels: Novel Anti-Allodynic Drug Candidates”
Regulonix has received a 12-month Phase I STTR grant from the National Institutes of Health for “Regulators of NaV1.7 Channels: Novel Anti-Allodynic Drug Candidates”